Baloğlu E, Ozyazici M, Baloğlu A, Ova L
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ege, Izmir, Turkey.
J Clin Pharm Ther. 2003 Apr;28(2):131-6. doi: 10.1046/j.1365-2710.2003.00472.x.
To compare the efficacy of 500 mg ornidazole vaginal ovules (VO) and vaginal tablets (VT) in the treatment of bacterial vaginosis.
Patients were allocated at random to one group of 50 subjects to be treated with a VO (500 mg) prepared in our laboratory and to a second group of 50 subjects to be treated with a VT of ornidazole (500 mg). Therapeutic efficacy was assessed by Nugent's scoring system and clinical criteria (Amsel's criteria) before and 1 week after treatment.
At the first follow-up visit, complete disappearance of the signs and symptoms or highly significant reduction in intensity of symptoms was observed in both treatment groups. No significant difference was evident between the two ornidazole formulations.
比较500毫克奥硝唑阴道栓（VO）和阴道片（VT）治疗细菌性阴道病的疗效。
将患者随机分为两组，每组50名。一组接受我们实验室制备的500毫克奥硝唑阴道栓治疗，另一组接受500毫克奥硝唑阴道片治疗。在治疗前及治疗1周后，采用纽金特评分系统和临床标准（阿姆斯尔标准）评估治疗效果。
在首次随访时，两个治疗组均观察到体征和症状完全消失或症状强度显著降低。两种奥硝唑制剂之间无明显差异。
